PepGen Inc. is developing oligonucleotide therapeutics to treat severe neuromuscular and neurologic diseases. The company's pipeline includes PGN-EDO51, PGN-EDO53, PGN-EDO45, and PGN-EDO44 to treat Duchenne Muscular Dystrophy, and PGN-EDODM1 to treat myotonic dystrophy type 1. PepGen was founded in 2018 and is headquartered in Cambridge, MA.